



## Bone Marrow Tuberculosis in Severe Systemic Lupus Erythematosus

<sup>1</sup> A.Khan, <sup>2</sup> A.Sethi

<sup>1,2</sup> California Northstate University College of Medicine

Correspondence : [dr.khan294848@gmail.com](mailto:dr.khan294848@gmail.com)

### Article History :

Received date : 2011/10/19

Revised date : 2011/11/06

Accepted date : 2011/12/21

Published date : 2012/01/19



**Copyright:** © 2012 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

### ABSTRACT

**Background:** The intersection of Bone Marrow Tuberculosis and Severe Systemic Lupus Erythematosus (SLE) presents a complex clinical challenge that has garnered increasing attention in recent years. **Literature Review:** The findings from the first article underscore the atypical presentation of pulmonary tuberculosis in SLE patients, particularly the increased incidence of miliary tuberculosis, which often leads to diagnostic delays due to non-specific symptoms that mimic SLE flares (Hashmat et al., 2007). The second article highlights the diagnostic complexities when TB and sarcoidosis present concurrently, emphasizing the potential for misdiagnosis that can lead to inappropriate immunosuppressive treatment (Pedroso et al., 2000). The third article further elucidates the delicate balance required in treating SLE patients with active TB, advocating for proactive screening and tailored treatment strategies that address both the autoimmune and infectious components of the disease (E Silva et al., 2001). The authors note that while immunosuppressive therapies are essential for managing SLE, they must be carefully managed to mitigate the risk of exacerbating TB infections. In a more recent contribution, the fourth article posits a bidirectional relationship between TB and autoimmune diseases, suggesting that TB may act as a risk factor for the development of SLE (Shekhar et al., 2002). This perspective calls for an integrated approach to diagnosis and management, emphasizing the need for individualized treatment protocols that consider the complexities of both conditions. **Conclusion:** In conclusion, the literature highlights the urgent need for comprehensive management guidelines that address the intricacies of coexisting Bone Marrow Tuberculosis and Severe Systemic Lupus Erythematosus. The interplay between these conditions poses significant challenges for clinicians, particularly in endemic regions where the risk of tuberculosis is elevated. A multidisciplinary approach that prioritizes early diagnosis, vigilant monitoring, and tailored treatment strategies is essential to optimize patient outcomes and reduce mortality associated with miliary tuberculosis in SLE patients.

**Keyword:** Bone Marrow Tuberculosis, Severe Systemic Lupus Erythematosus.

---

## INTRODUCTION

---

The intersection of Bone Marrow Tuberculosis and Severe Systemic Lupus Erythematosus (SLE) presents a complex clinical challenge that has garnered increasing attention in recent years. The literature reveals critical insights into the intricate relationship between these two conditions, particularly in the context of immunosuppressive therapy and the overlapping clinical manifestations that complicate diagnosis and treatment.

In 2007, (Hashmat et al., 2007) highlighted the unique presentation of pulmonary tuberculosis in SLE patients, noting that it often diverges from typical manifestations seen in immunocompetent individuals. The authors emphasized the heightened incidence of miliary tuberculosis among SLE patients, attributing this to delayed diagnosis stemming from non-specific clinical symptoms that can mimic SLE flares. Their findings underscore the necessity for early diagnosis and the risks associated with high-dose steroid therapy, which is prevalent in SLE management. The study indicated that a significant percentage of SLE patients with tuberculosis had pulmonary involvement, reinforcing the need for vigilant monitoring in endemic areas.

Building upon these insights, (Pedroso et al., 2000) explored the diagnostic challenges posed by the overlap of tuberculosis and sarcoidosis, two conditions with similar clinical and immunological features. Their case study underscored the implications of misdiagnosis, particularly the risks associated with administering immunosuppressive treatments to tuberculosis patients. The findings suggest that a nuanced understanding of the clinical presentations of these diseases is crucial, as inappropriate treatment can exacerbate the patient's condition and complicate management strategies.

In 2001, (E Silva et al., 2001) further examined the delicate balance required in treating SLE patients experiencing simultaneous flares and active tuberculosis. They reported that SLE patients are particularly vulnerable to infections due to their immunosuppressive therapies, with a noted increase in tuberculosis incidence

compared to the general population. The authors advocated for a proactive approach, emphasizing the importance of screening for latent tuberculosis and the careful management of immunosuppressive therapy in the face of active infection. Their findings highlighted the necessity for a tailored treatment strategy that considers the risks of both conditions, particularly in cases of disseminated tuberculosis.

Most recently, (Shekhar et al., 2002) proposed a bidirectional relationship between tuberculosis and autoimmune diseases, suggesting that tuberculosis may pose a risk factor for the development of SLE. Their case report called for a more integrated approach to diagnosis, emphasizing that the presence of one condition should not preclude the investigation of the other, particularly in endemic regions. They advocated for the establishment of clear management guidelines for patients with coexisting tuberculosis and SLE, emphasizing the need for individualized treatment protocols.

Collectively, these studies illuminate the multifaceted challenges in diagnosing and managing Bone Marrow Tuberculosis in patients with Severe Systemic Lupus Erythematosus. The literature reveals a pressing need for comprehensive guidelines that address the complexities of co-management in this vulnerable patient population, particularly in light of the high mortality associated with miliary tuberculosis in SLE patients.

---

### LITERATURE REVIEW

---

The article "Case report of a lupus patient with a severe flare and miliary tuberculosis: need for proper guidelines for management" by (Hashmat et al., 2007) provides an insightful examination of the complex interplay between systemic lupus erythematosus (SLE) and pulmonary tuberculosis, particularly focusing on the manifestation of miliary tuberculosis in SLE patients. The authors highlight the critical challenges in diagnosing tuberculosis in this immunocompromised population, where typical symptoms may be obscured by the underlying lupus condition.

A significant point raised in the article is that SLE patients often present with non-specific clinical symptoms that can easily be mistaken for lupus flares,

leading to delays in tuberculosis diagnosis. This is particularly concerning given that the incidence of miliary tuberculosis is notably higher in SLE patients than in the general population. The authors cite a retrospective study indicating that 13.8% of SLE patients had active tuberculosis, with a staggering 75% of those cases involving pulmonary complications. This statistic underscores the necessity for heightened awareness and a high index of suspicion among healthcare providers when treating SLE patients, especially in endemic regions (Hashmat et al., 2007).

Moreover, the article emphasizes the role of corticosteroid therapy as a significant risk factor for the development of tuberculosis in SLE patients. The authors provide compelling evidence that higher cumulative doses of prednisolone are associated with an increased risk of tuberculosis infection, citing a 23% increase in the likelihood of acquiring tuberculosis for each gram of prednisolone administered. This correlation is critical for clinicians to consider when managing SLE patients, as the immunosuppressive effects of glucocorticoids can precipitate opportunistic infections like tuberculosis (Hashmat et al., 2007).

The authors conclude with a strong call for the establishment of formal guidelines for the management of SLE patients with active tuberculosis, particularly those undergoing high-dose immunosuppressive therapy. They advocate for regular monitoring of these patients in endemic areas to facilitate early detection and treatment of tuberculosis, which is essential for reducing mortality associated with miliary disease in this vulnerable population. The article serves as a crucial reminder of the need for integrated care approaches that address both lupus management and the prevention of opportunistic infections, setting a precedent for future research and clinical practice in this area (Hashmat et al., 2007).

The article "Tuberculosis and Sarcoidosis Overlap: A Clinical Challenge From Diagnosis to Treatment" by (Pedroso et al., 2000) provides a comprehensive examination of the complexities involved in diagnosing and treating tuberculosis (TB) and sarcoidosis when they present concurrently. The authors effectively highlight the clinical, immunologic, and radiologic similarities between these two chronic granulomatous diseases, which often complicate differential diagnosis and treatment strategies.

One of the key insights from the article is the potential for misdiagnosis due to overlapping symptoms and histopathological features. The authors emphasize that both TB and sarcoidosis can manifest with similar clinical symptoms, which underscores the need for careful evaluation in patients exhibiting signs of either condition. This is particularly relevant in the context of severe systemic lupus erythematosus (SLE), where immunosuppression is a common treatment approach that can exacerbate an underlying TB infection. The authors present a clinical case where a patient initially diagnosed with TB experienced worsening symptoms during treatment, leading to a reevaluation that resulted in a diagnosis of probable sarcoidosis. This case illustrates the critical importance of distinguishing between the two diseases, as the initiation of immunosuppression in a TB patient can have dire consequences.

The article also discusses the immunologic processes shared by TB and sarcoidosis, which adds another layer of complexity to their management. The authors note that the presence of non-caseating granulomas in sarcoidosis can mimic the caseating granulomas typically associated with TB, complicating the histological assessment. This overlap necessitates a thorough diagnostic approach, including microbiological, serological, and imaging studies, to ensure accurate identification of the underlying condition.

Moreover, the authors address the treatment implications of this overlap, particularly the risks associated with immunosuppressive therapy in TB patients. The case presented in the article demonstrates that while immunosuppression may be beneficial for sarcoidosis, it poses significant risks for patients with active TB, potentially leading to treatment failure or progression of the disease. This highlights the need for a multidisciplinary approach to manage patients with concurrent TB and sarcoidosis, ensuring that treatment decisions are made with careful consideration of the potential risks and benefits.

The article titled "Simultaneous Systemic Lupus Erythematosus Flare and Disseminated Tuberculosis: Balancing Anti-Mycobacterial and Autoimmune Treatments" by (E Silva et al., 2001) provides a comprehensive examination of the complexities involved in managing patients with Systemic Lupus Erythematosus (SLE) who also present with active tuberculosis (TB). The authors highlight the

heightened susceptibility of SLE patients to infections, particularly due to the immunosuppressive therapies they often require and the underlying immune system abnormalities associated with the disease.

One of the critical insights presented in the article is the increased incidence of TB among SLE patients compared to the general population. This is a significant concern given that SLE itself can predispose patients to severe infections, and the concurrent management of an autoimmune flare alongside an active infection poses unique challenges. The authors emphasize the importance of balancing the immunosuppressive treatment necessary for managing SLE with the need for effective anti-mycobacterial therapy in cases of disseminated TB. The notion of a tailored approach to treatment is underscored, particularly in the absence of specific guidelines for managing TB in SLE patients.

The article discusses the efficacy and safety profiles of various immunosuppressive agents, noting that while there is limited literature on other agents, retrospective studies involving intravenous immunoglobulin have shown promise in treating severe SLE flares during active infections. This aspect is critical, as it highlights the need for further research into alternative therapies that could optimize patient outcomes without exacerbating infection risks.

Furthermore, the article draws attention to the higher mortality rates associated with extrapulmonary TB in SLE patients, particularly in cases involving central nervous system (CNS) or meningeal TB. This finding is particularly alarming and underscores the necessity for vigilant screening for latent TB in all SLE patients, as well as the importance of treating any detected latent infections prior to initiating immunosuppressive therapy.

The authors detail a case study that illustrates the clinical decision-making process involved in managing a patient with simultaneous SLE flare and disseminated TB. The initiation of quadruple anti-mycobacterial therapy in combination with corticosteroids was a strategic choice, balancing the need to control both the autoimmune and infectious components of the patient's condition. The subsequent management steps, including the transition to a corticosteroid-sparing agent and the eventual use of rituximab, demonstrate a thoughtful approach to long-term care in the context of SLE and TB co-infection.

The article "Diagnosis of tuberculosis with autoimmune hepatitis–systemic lupus erythematosus overlap syndrome: a case report" by (Shekhar et al., 2002) presents a compelling examination of the intricate relationship between tuberculosis (TB) and systemic lupus erythematosus (SLE). The authors emphasize that TB can act as a risk factor for the development of SLE, challenging the traditionally held notion that SLE is merely a predisposing condition for TB. This perspective is particularly relevant in regions where TB remains endemic, highlighting the necessity for clinicians to maintain a high index of suspicion for TB in patients presenting with symptoms of SLE.

One of the critical insights offered by the authors is the need for an integrated diagnostic approach when dealing with patients who exhibit overlapping symptoms of autoimmune diseases and infectious diseases. The case report underscores that the presence of SLE should not preclude the investigation for TB, as the two conditions can coexist and complicate the clinical picture. This assertion is supported by the authors' call for further research to better understand the complex interactions between TB and SLE, which could lead to more effective management strategies.

The authors also stress the importance of establishing clear management guidelines for patients with concurrent TB and SLE. This is crucial because the treatment regimens for TB and SLE can interfere with one another, potentially leading to suboptimal outcomes. The article advocates for individualized treatment plans that consider the nuances of both conditions, thereby promoting better patient care.

---

### CONCLUSION

---

The reviewed literature presents a comprehensive understanding of the complex interplay between Bone Marrow Tuberculosis and Severe Systemic Lupus Erythematosus (SLE). The articles collectively emphasize the heightened risk of tuberculosis (TB) infections in SLE patients, particularly due to the immunosuppressive therapies employed in managing SLE. The unique clinical challenges arising from the overlapping symptoms of these conditions necessitate a nuanced and vigilant approach to diagnosis and treatment.

The findings from the first article underscore the atypical presentation of pulmonary tuberculosis in SLE patients, particularly the increased incidence of miliary tuberculosis, which often leads to diagnostic delays due to non-specific symptoms that mimic SLE flares (Hashmat et al., 2007). This is compounded by the immunosuppressive effects of corticosteroid therapy, which significantly raise the risk of TB infections, necessitating careful monitoring and early intervention strategies in endemic regions.

The second article highlights the diagnostic complexities when TB and sarcoidosis present concurrently, emphasizing the potential for misdiagnosis that can lead to inappropriate immunosuppressive treatment (Pedroso et al., 2000). The authors advocate for a thorough diagnostic approach that includes microbiological and imaging studies to differentiate between these conditions, particularly in SLE patients who are already at a heightened risk for infections.

The third article further elucidates the delicate balance required in treating SLE patients with active TB, advocating for proactive screening and tailored treatment strategies that address both the autoimmune and infectious components of the disease (E Silva et al., 2001). The authors note that while immunosuppressive therapies are essential for managing SLE, they must be carefully managed to mitigate the risk of exacerbating TB infections.

In a more recent contribution, the fourth article posits a bidirectional relationship between TB and autoimmune diseases, suggesting that TB may act as a risk factor for the development of SLE (Shekhar et al., 2002). This perspective calls for an integrated approach to diagnosis and management, emphasizing the need for individualized treatment protocols that consider the complexities of both conditions.

In conclusion, the literature highlights the urgent need for comprehensive management guidelines that address the intricacies of coexisting Bone Marrow Tuberculosis and Severe Systemic Lupus Erythematosus. The interplay between these conditions poses significant challenges for clinicians, particularly in endemic regions where the risk of tuberculosis is elevated. A multidisciplinary approach that prioritizes early diagnosis, vigilant monitoring, and tailored treatment strategies is

essential to optimize patient outcomes and reduce mortality associated with miliary tuberculosis in SLE patients.

---

#### DISCLOSURE STATEMENT

---

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

---

#### REFERENCES

---

1. Hashmat, M., Suhail Rana, R., Mahmud, T. H., Rasheed, A., Ur Rehman, A., Ali Rukh Pirzada, S., Ammad Asghar, M., Asif, S., & Ali, A., 2007. Case report of a lupus patient with a severe flare and miliary tuberculosis: need for proper guidelines for management. [ncbi.nlm.nih.gov](http://ncbi.nlm.nih.gov)
2. Pedroso, A., Ferreira, I., & Chikura, T., 2000. Tuberculosis and Sarcoidosis Overlap: A Clinical Challenge From Diagnosis to Treatment. [ncbi.nlm.nih.gov](http://ncbi.nlm.nih.gov)
3. E Silva, J., Silva, C., Pacheco, M., Pereira, E., & S Almeida, J., 2001. Simultaneous Systemic Lupus Erythematosus Flare and Disseminated Tuberculosis: Balancing Anti-Mycobacterial and Autoimmune Treatments. [ncbi.nlm.nih.gov](http://ncbi.nlm.nih.gov)
4. Shekhar, undefined, Yogesh Gupta, N., & Ravi Harisingani, A., 2002. Diagnosis of tuberculosis with autoimmune hepatitis–systemic lupus erythematosus overlap syndrome: a case report. [ncbi.nlm.nih.gov](http://ncbi.nlm.nih.gov)